<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ab Science Sa — News on 6ix</title>
    <link>https://6ix.com/company/ab-science-sa-1</link>
    <description>Latest news and press releases for Ab Science Sa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 16 Apr 2026 17:20:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ab-science-sa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52724beedb30cb6f69aa2.webp</url>
      <title>Ab Science Sa</title>
      <link>https://6ix.com/company/ab-science-sa-1</link>
    </image>
    <item>
      <title>AB Science provides an update on its clinical development program.</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-provides-an-update-on-its-clinical-development-program</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-provides-an-update-on-its-clinical-development-program</guid>
      <pubDate>Thu, 16 Apr 2026 17:20:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS THE POLICY COVERS UP TO EUR 25 MILLION OF TRIAL COSTS IN THE EVENT OF CLINICAL FAILURE, WITH ZERO DEDUCTIBLE THIS RISK-TRANSFER STRUCTURE PROTECTS SHAREHOLDER CAPITAL AND SIGNALS INSTITUTIONAL CONFIDENCE IN THE MASITINIB PROGRAMME AB SCIENCE IMPLEMENTS A VOLUNTARY TEMPORARY HALT IN EUROPE OF ITS CLINICAL TRIALS, BE</description>
    </item>
    <item>
      <title>AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-identification-of-a-plasma-biomarker-that-indicates-the-activity-of-masitinib-in-treating-als</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-identification-of-a-plasma-biomarker-that-indicates-the-activity-of-masitinib-in-treating-als</guid>
      <pubDate>Tue, 24 Feb 2026 17:02:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO INFLAMATORY MICROGLIA, WHICH ARE TARGETED BY MASITINIB THIS BIOMARKER IS ALSO APPLICABLE TO PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AND ALZHEIMER DISEASE THIS BIOMARKER CAN BE STRATEGIC TO DETERMINE WHICH PATIENTS RESPOND TO TREATMENT AND POTENTIALLY INCREASE CHANCE OF REGISTRATION IN N</description>
    </item>
    <item>
      <title>AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announced-that-the-food-and-drug-administration-fda-granted-the-status-of-minor-use-in-major-species-mums-for-masivetr-in-the-treatment-of-canine-mast-cell-tumors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announced-that-the-food-and-drug-administration-fda-granted-the-status-of-minor-use-in-major-species-mums-for-masivetr-in-the-treatment-of-canine-mast-cell-tumors-1</guid>
      <pubDate>Mon, 09 Feb 2026 17:05:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL HEALTH FRANCHISE Paris, February 9, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors. Masivet® is a targeted</description>
    </item>
    <item>
      <title>AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-receives-notice-of-allowance-for-us-patent-covering-masitinib-in-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-receives-notice-of-allowance-for-us-patent-covering-masitinib-in-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-1</guid>
      <pubDate>Thu, 29 Jan 2026 17:01:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA PATENT OFFICE STRENGTHENS THE COMPANY’S INTELLECTUAL PROPERTY POSITION IN THIS INDICATION UNTIL 2042, ADDING TO THE COVERAGE ALREADY GRANTED IN EUROPE Paris, January 29, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced that the United States Patent and Trademark Office (USPTO) is</description>
    </item>
    <item>
      <title>AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-receives-japanese-patent-protection-for-the-use-of-masitinib-in-progressive-forms-of-multiple-sclerosis-ms-until-2041-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-receives-japanese-patent-protection-for-the-use-of-masitinib-in-progressive-forms-of-multiple-sclerosis-ms-until-2041-1</guid>
      <pubDate>Wed, 21 Jan 2026 17:02:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASITINIB HAS UNIQUE AND COMPETITIVE POSITIONING IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS DUE TO ITS DISTINCTIVE SAFETY AND EFFICACY PROFILE AND MECANISM OF ACTIONS TARGETING BOTH MICROGLIA AND MAST CELLS Paris, January 21, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced tha</description>
    </item>
    <item>
      <title>AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-reports-fourth-consecutive-case-of-response-from-phase-1-data-for-the-combination-of-ab8939-with-venetoclax-for-the-treatment-of-refractory-or-relapsed-acute-myeloid-leukemia-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-reports-fourth-consecutive-case-of-response-from-phase-1-data-for-the-combination-of-ab8939-with-venetoclax-for-the-treatment-of-refractory-or-relapsed-acute-myeloid-leukemia-1</guid>
      <pubDate>Wed, 07 Jan 2026 17:03:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA The combination treatment was well-tolerated, with no hematological toxicity and no dose limiting toxicity The fourth patient had a complex karyotype including a monosomy of chromosome 5 and TP53 mutation, and was in the third-line of treatment. He had a near complete response after 14 days of treat</description>
    </item>
    <item>
      <title>AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-patent-for-masitinib-in-the-treatment-of-sickle-cell-disease-formally-granted-in-the-us-with-a-protection-until-2040-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-patent-for-masitinib-in-the-treatment-of-sickle-cell-disease-formally-granted-in-the-us-with-a-protection-until-2040-1</guid>
      <pubDate>Mon, 22 Dec 2025 16:58:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY PORTFOLIO WITH LONG-TERM PROTECTION FOR AN ADDITIONAL INDICATION WITH A HIGH UNMET MEDICAL NEED THE BIOMARKER PHASE 2 IN COOPERATION WITH AP-HP IS FULLY FUNDED Paris, December 22, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Of</description>
    </item>
    <item>
      <title>AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-initiation-of-coverage-of-its-stock-by-maxim-group-with-a-target-price-of-eur-40-per-share-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-initiation-of-coverage-of-its-stock-by-maxim-group-with-a-target-price-of-eur-40-per-share-1</guid>
      <pubDate>Thu, 18 Dec 2025 18:17:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm. Maxim Group began covering the stock with a study entitled “Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starti</description>
    </item>
    <item>
      <title>AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-a-new-publication-on-biorxiv-that-identifies-ab8939-as-a-promising-drug-candidate-for-treating-refractory-acute-myeloid-leukemia-and-potentially-other-cancers-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-a-new-publication-on-biorxiv-that-identifies-ab8939-as-a-promising-drug-candidate-for-treating-refractory-acute-myeloid-leukemia-and-potentially-other-cancers-1</guid>
      <pubDate>Mon, 15 Dec 2025 17:39:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND POTENTIALLY OTHER CANCERS AB8939 is a promising drug candidate for refractory AML, especially for cases with poor prognoses such as complex karyotypes, MECOM rearrangements, and TP53 mutations AB8939 has dual action against both proliferating tumor cells (via tubulin disru</description>
    </item>
    <item>
      <title>AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-new-publication-on-medrxiv-highlighting-clinical-benefit-with-masitinib-in-amyotrophic-lateral-sclerosis-patients-prior-any-complete-loss-of-function-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-new-publication-on-medrxiv-highlighting-clinical-benefit-with-masitinib-in-amyotrophic-lateral-sclerosis-patients-prior-any-complete-loss-of-function-1</guid>
      <pubDate>Thu, 11 Dec 2025 17:29:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant improvement in functional decline measured by the ALSFRS-R score, with a 4.04-point difference favoring masitinib over placebo (p=0.0065)Significant benefit on CAFS (relative benefit +20.2%, p=0.0290)Median progression-free survival (PFS) extended by 9 months (p=0.0057)Median overall survival (OS) incr</description>
    </item>
    <item>
      <title>AB Science announces the successful completion of a EUR 2.8 million private placement</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-successful-completion-of-a-eur-28-million-private-placement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-successful-completion-of-a-eur-28-million-private-placement-1</guid>
      <pubDate>Fri, 17 Oct 2025 06:00:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.8 MILLION PRIVATE PLACEMENT AB SCIENCE IS FULLY FINANCED TO FINISH PHASE 1 OF AB8939 IN AML AND TO EXECUTE AN EXPANSION PHASE TO MAXIMIZE CHANCE OF SUCCESS OF FUTURE REGISTRATION STUDY Paris, October 17, 2025, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed by a limited numbe</description>
    </item>
    <item>
      <title>AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-provides-intitial-phase-1-data-for-the-combination-of-ab8939-with-venetoclax-for-the-treatment-of-refractory-or-relapsed-acute-myeloid-leukemia-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-provides-intitial-phase-1-data-for-the-combination-of-ab8939-with-venetoclax-for-the-treatment-of-refractory-or-relapsed-acute-myeloid-leukemia-1</guid>
      <pubDate>Thu, 16 Oct 2025 18:57:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 16 October 2025, 9pm CET AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its AB8939 program in acute myeloid leukemia (AML). The webcast presentation is available on the company’s website, in the section « Press Releases »: https://www.ab-science.com/news-and-media/press-releases/ Highlights of the</description>
    </item>
    <item>
      <title>AB Science will hold a virtual conference on Thursday, October 16, 2025  from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-will-hold-a-virtual-conference-on-thursday-october-16-2025-from-2pm-to-3pm-cet-to-provide-an-update-on-the-phase-1-study-with-ab8939-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-will-hold-a-virtual-conference-on-thursday-october-16-2025-from-2pm-to-3pm-cet-to-provide-an-update-on-the-phase-1-study-with-ab8939-1</guid>
      <pubDate>Tue, 14 Oct 2025 06:36:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML WITH VERY UNFAVORABLE GENETIC PROFILES, ARE RESPONDING TO TREATMENT The combination treatment is well-tolerated, with no hematological toxicityThe disease control rate is 100% (3/3)The partial response rate is 100% (3/3), including one patient in complete remission These results were ob</description>
    </item>
    <item>
      <title>AB Science today reports its revenues for the first half of 2025 and provides an update on its activities</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-today-reports-its-revenues-for-the-first-half-of-2025-and-provides-an-update-on-its-activities-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-today-reports-its-revenues-for-the-first-half-of-2025-and-provides-an-update-on-its-activities-1</guid>
      <pubDate>Fri, 10 Oct 2025 16:10:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2025 AND KEY EVENTS DURING THE PERIOD Financial and corporate situation Operating deficit reduced by 24% compared to the first half of 2024, amounting to €2.7 million as of June 30, 2025Capital increase through private placements for a total amount of €6.3 million Clinical development Masitinib platform: Authorization from several European countries for the confirmatory Phase 3 study with masitinib in amyotrophic later</description>
    </item>
    <item>
      <title>AB Science announces a slight delay in the publication of its 2025 half-year financial report</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-a-slight-delay-in-the-publication-of-its-2025-half-year-financial-report-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-a-slight-delay-in-the-publication-of-its-2025-half-year-financial-report-1</guid>
      <pubDate>Tue, 30 Sep 2025 16:32:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2025 HALF-YEAR FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2025 ON OCTOBER 10, 2025, AT THE LATEST Paris, September 30 2025, 6.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its financial report for the first half of 2025, initially scheduled for 30 September 2025, to give the auditors time to complete their audit work. The C</description>
    </item>
    <item>
      <title>AB Science announces the successful completion of a 2.55 million euros private placement</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-successful-completion-of-a-255-million-euros-private-placement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-successful-completion-of-a-255-million-euros-private-placement-1</guid>
      <pubDate>Mon, 04 Aug 2025 05:58:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.55 MILLION PRIVATE PLACEMENT Paris, August 4, 2025, 8am CET AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors (the “Private Placement”). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Aut</description>
    </item>
    <item>
      <title>AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-receives-regulatory-approval-from-european-countries-to-initiate-third-stage-of-phase-iii-study-combining-its-molecule-ab8939-with-venetoclax-for-the-treatment-of-aml-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-receives-regulatory-approval-from-european-countries-to-initiate-third-stage-of-phase-iii-study-combining-its-molecule-ab8939-with-venetoclax-for-the-treatment-of-aml-1</guid>
      <pubDate>Wed, 30 Jul 2025 05:46:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 TARGETING MICROTUBULE AND STEM CELLS AND VENETOCLAX TARGETING BCL-2 SHOWS POTENTIAL SYNERGISTIC EFFICACY AND GOOD HEMATOLOGICAL TOLERANCE COMPARED WITH STANDARD OF CARE CHEMOTHERAPIES, IN PARTICULAR IN THE POOR RESPONDERS TO STANDARD OF CARE CHEMOTHERAPIES TREAT</description>
    </item>
    <item>
      <title>AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-has-received-approval-from-several-european-countries-to-initiate-the-confirmatory-phase-3-study-of-masitinib-in-als-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-has-received-approval-from-several-european-countries-to-initiate-the-confirmatory-phase-3-study-of-masitinib-in-als-1</guid>
      <pubDate>Thu, 24 Jul 2025 05:57:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL VALIDATION BY THE EMA AND FDA AUTHORIZATION Paris, July 24, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis (ALS), study AB23005, has been authorized by the first set of European countries (</description>
    </item>
    <item>
      <title>AB Science announces the successful completion of a EUR 1.925 million private placement</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-successful-completion-of-a-eur-1925-million-private-placement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-announces-the-successful-completion-of-a-eur-1925-million-private-placement-1</guid>
      <pubDate>Tue, 08 Jul 2025 06:02:00 GMT</pubDate>
      <description>PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925 MILLION PRIVATE PLACEMENT Paris, July 8, 2025, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors (the “Private Placement”). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authori</description>
    </item>
    <item>
      <title>AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer</title>
      <link>https://6ix.com/company/ab-science-sa-1/news/ab-science-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer-1</link>
      <guid isPermaLink="true">https://6ix.com/company/ab-science-sa-1/news/ab-science-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer-1</guid>
      <pubDate>Fri, 04 Jul 2025 06:01:00 GMT</pubDate>
      <description>PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO BENEFIT Paris, July 4, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer (study AB22007) has been authorized by FDA and EMA (harmonized protocol approved through s</description>
    </item>
  </channel>
</rss>